Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 11:17:1214972.
doi: 10.3389/fnins.2023.1214972. eCollection 2023.

Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder

Maria Gałuszko-Wȩgielnik  1 , Katarzyna Jakuszkowiak-Wojten  1 , Mariusz Stanisław Wiglusz  1 , Wiesław Jerzy Cubała  1 , Michał Pastuszak  1
Affiliations

Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder

Maria Gałuszko-Wȩgielnik et al. Front Neurosci. .

Abstract

Background: Psychotic treatment-resistant depression represents a complex and challenging form of mood disorder in clinical practice. Despite its severity, psychotic depression is frequently underdiagnosed and inadequately treated. Ketamine has demonstrated rapid and potent antidepressant effects in clinical studies, while exhibiting a favorable safety and tolerability profile. Although there is limited literature available on the use of ketamine in psychotic TRD, reports on its efficacy, safety, and tolerability profile are of great interest to clinicians. The aim of this study is to investigate the relationship between dissociative symptomatology and psychomimetic effects in inpatients with treatment-resistant major psychotic depression and treatment-resistant bipolar psychotic depression, who receive intravenous ketamine treatment alongside psychotropic medication, both during and after treatment.

Materials and methods: A total of 36 patients diagnosed with treatment-resistant unipolar (17 patients) or bipolar (18 patients) depression with psychotic features were treated with eight intravenous infusions of 0.5 mg/kg ketamine twice a week over 4 weeks. Ketamine was given in addition to their standard of care treatment. The severity of depressive symptoms was evaluated using the MADRS, while dissociative and psychomimetic symptoms were assessed using the CADSS and BPRS, respectively.

Results: There were no statistically significant changes observed in MADRS, CADSS, and BPRS scores within the study group during ketamine infusions. However, significant improvements in MADRS, CADSS, and BPRS scores were observed during ketamine infusions in both the unipolar and bipolar depression groups.

Conclusion: This study provides support for the lack of exacerbation of psychotic symptoms in both unipolar and bipolar depression.

Keywords: bipolar depression; dissociation; ketamine; psychotic depression; treatment-resistant depression.

PubMed Disclaimer

Conflict of interest statement

WC has received Grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, BMS, Celon, Cephalon, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, Minerva, MSD, NIH, Novartis, Orion, Otsuka, Sanofi, Servier. Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva. Advisory boards: Angelini, Celon (terminated), Douglas Pharmaceuticals, Janssen, MSD, Novartis, Sanofi; MG-W has received research support from Alkermes, Biogen, Celon, Janssen, KCR, Minerva Neurosciences, Lilly, and Servier, Novartis; KJ-W has received research support from Alkermes, Auspex, Biogen, Celon, Gedeon-Richter, GW Pharmaceuticals, Janssen, KCR, Lilly, Lundbeck, Minerva Neurosciences, Orion, Otsuka, and Servier; MW has received research support from Alkermes, Auspex Pharmaceuticals, Biogen, Cephalon, Celon, Cortexyme, Eli Lilly, Ferrier, Forest Laboratories, GedeonRichter, GWPharmaceuticals, Janssen, Lundbeck, Orion, Otsuka, and Servier; Speakers bureau: Lundbeck, Servier. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Means and standard errors for MADRS scores over the time of ketamine treatment in studied groups.
FIGURE 2
FIGURE 2
Means and standard errors for MADRS-item 10 (suicidal thoughts) scores over the time of ketamine treatment in studied groups.
FIGURE 3
FIGURE 3
Means and standard errors for YMRS scores over the time of ketamine treatment in studied groups.
FIGURE 4
FIGURE 4
Means and standard errors for CADSS scores measured before the ketamine infusions in studied groups.
FIGURE 5
FIGURE 5
Means and standard errors for CADSS scores measured 30 min after the ketamine infusions in studied groups.
FIGURE 6
FIGURE 6
Means and standard errors for BPRS scores measured before the ketamine infusions in studied groups.
FIGURE 7
FIGURE 7
Means and standard errors for BPRS scores measured 30 min after the ketamine infusions in studied groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abbar M., Demattei C., El-Hage W., Llorca P. M., Samalin L., Demaricourt P., et al. (2022). Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ 2:e067194. 10.1136/bmj-2021-067194 - DOI - PMC - PubMed
    1. Ajub E., Lacerda A. L. T. (2018). Efficacy of esketamine in the treatment of depression with psychotic features: A Case Series. Biol. Psychiatry 83 e15–e16. 10.1016/j.biopsych.2017.06.011 - DOI - PubMed
    1. Allen N. D., Rodysill B. R., Bostwick J. M. (2019). A report of affective switching associated with ketamine: The case of ketamine-induced mania is not closed. Bipolar. Disord. 2 176–178. 10.1111/bdi.12728 - DOI - PubMed
    1. Beck K., Hindley G., Borgan F., Ginestet C., McCutcheon R., Brugger S., et al. (2020). Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: A systematic review and meta-analysis. JAMA 3:e204693. 10.1001/jamanetworkopen.2020.4693 - DOI - PMC - PubMed
    1. Bennett R., Yavorsky C., Bravo G. (2022). Ketamine for bipolar depression: biochemical, psychotherapeutic, and psychedelic approaches. Front. Psychiatry 13:867484. 10.3389/fpsyt.2022.867484 - DOI - PMC - PubMed

LinkOut - more resources